PL1613304T3 - Inhibitory DPP-IV - Google Patents

Inhibitory DPP-IV

Info

Publication number: PL1613304T3
Authority: PL; Poland
Prior art keywords: dpp; inhibitors; compounds; relates; medicament
Prior art date: 2003-12-09

Application number

PL04803694T

Other languages

English (en)

Inventor

Paul John Edwards

Meritxell Lopez-Canet

Achim Feurer

Silvia Cerezo-Galvez

Victor Giulio Matassa

Sonja Nordhoff

Meinolf Thiemann

Oliver Hill

Original Assignee

Santhera Pharmaceuticals Schweiz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-09

Filing date

2004-12-09

Publication date

2008-02-29

2004-12-09 Application filed by Santhera Pharmaceuticals Schweiz Ag filed Critical Santhera Pharmaceuticals Schweiz Ag

2008-02-29 Publication of PL1613304T3 publication Critical patent/PL1613304T3/pl

Links

239000003112 inhibitor Substances 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract 3
108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Ophthalmology & Optometry (AREA)

PL04803694T 2003-12-09 2004-12-09 Inhibitory DPP-IV PL1613304T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP03028211A EP1541143A1 (en)	2003-12-09	2003-12-09	Dpp-iv inhibitors
PCT/EP2004/014040 WO2005056003A1 (en)	2003-12-09	2004-12-09	Dpp-iv inhibitors
EP04803694A EP1613304B1 (en)	2003-12-09	2004-12-09	Dpp-iv inhibitors

Publications (1)

Publication Number	Publication Date
PL1613304T3 true PL1613304T3 (pl)	2008-02-29

Family

ID=34486147

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04803694T PL1613304T3 (pl)	2003-12-09	2004-12-09	Inhibitory DPP-IV

Country Status (23)

Country	Link
US (1)	US20080027035A1 (pl)
EP (2)	EP1541143A1 (pl)
JP (1)	JP2007513910A (pl)
KR (1)	KR100845397B1 (pl)
CN (1)	CN1905868A (pl)
AT (1)	ATE372767T1 (pl)
AU (1)	AU2004296553B2 (pl)
BR (1)	BRPI0417458A (pl)
CA (1)	CA2548742A1 (pl)
CY (1)	CY1106969T1 (pl)
DE (1)	DE602004008895T2 (pl)
DK (1)	DK1613304T3 (pl)
ES (1)	ES2291966T3 (pl)
HR (1)	HRP20070560T3 (pl)
IL (1)	IL176062A0 (pl)
MX (1)	MXPA06006652A (pl)
NO (1)	NO20062644L (pl)
PL (1)	PL1613304T3 (pl)
PT (1)	PT1613304E (pl)
RU (1)	RU2006119302A (pl)
SI (1)	SI1613304T1 (pl)
WO (1)	WO2005056003A1 (pl)
ZA (1)	ZA200604719B (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2296979T3 (es)	2001-06-27	2008-05-01	Smithkline Beecham Corporation	Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
WO2004064778A2 (en)	2003-01-17	2004-08-05	Merck & Co. Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004069162A2 (en)	2003-01-31	2004-08-19	Merck & Co., Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004103276A2 (en)	2003-05-14	2004-12-02	Merck & Co., Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004110436A1 (en)	2003-06-06	2004-12-23	Merck & Co., Inc.	Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CN1809544A (zh)	2003-06-17	2006-07-26	麦克公司	作为二肽基肽酶抑制剂用于治疗或预防糖尿病的环己基甘氨酸衍生物
AU2004261186A1 (en)	2003-07-31	2005-02-10	Merck & Co., Inc.	Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
CN1950349A (zh)	2004-05-04	2007-04-18	默克公司	作为用于治疗或预防糖尿病的二肽基肽酶－ⅳ抑制剂的1,2,4－噁二唑衍生物
AU2005247895A1 (en)	2004-05-18	2005-12-08	Merck & Co., Inc.	Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2006098342A1 (en) *	2005-03-16	2006-09-21	Astellas Pharma Inc.	Piperazinyl compounds
EP1943215A2 (en)	2005-10-31	2008-07-16	Brystol-Myers Squibb Company	Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
GB0526291D0 (en)	2005-12-23	2006-02-01	Prosidion Ltd	Therapeutic method
US20090156465A1 (en)	2005-12-30	2009-06-18	Sattigeri Jitendra A	Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
AU2007235876A1 (en)	2006-04-12	2007-10-18	Probiodrug Ag	Enzyme inhibitors
EP1905759A1 (en) *	2006-09-07	2008-04-02	Santhera Pharmaceuticals (Schweiz) AG	N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment oftype 2 diabetes mellitus
WO2008028662A1 (en) *	2006-09-07	2008-03-13	Santhera Pharmaceuticals (Schweiz) Ag	N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment of type 2 diabetes mellitus
EP2089383B1 (en)	2006-11-09	2015-09-16	Probiodrug AG	3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en)	2006-11-30	2015-09-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase
KR20080071476A (ko) *	2007-01-30	2008-08-04	주식회사 엘지생명과학	신규한 디펩티딜 펩티데이즈 ｉｖ(ｄｐｐ-ｉｖ) 저해제
JP5667440B2 (ja)	2007-04-18	2015-02-12	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
ES2526338T3 (es) *	2007-04-19	2015-01-09	Dong-A Pharm.Co., Ltd.	Inhibidor de DPP-IV que incluye grupo beta-amino, método de preparación del mismo y composición farmacéutica que contiene el mismo para prevernir y tratar diabetes u obesidad
US7860904B2 (en) *	2007-04-24	2010-12-28	Microsoft Corporation	Standalone execution of incomplete data flows
EP2019099A1 (en) *	2007-07-02	2009-01-28	Santhera Pharmaceuticals (Schweiz) AG	Dpp-IV inhibitors
WO2009003681A1 (en) *	2007-07-02	2009-01-08	Santhera Pharmaceuticals (Schweiz) Ag	Dpp-iv inhibitors
CN102838589B (zh) *	2008-09-23	2014-03-26	成都地奥制药集团有限公司	经甲磺酰化的制备n取代的吡咯烷衍生物的方法
CN101823987B (zh) *	2009-03-06	2014-06-04	中国科学院上海药物研究所	一类新的dpp-ⅳ抑制剂及其制备方法和用途
UA107360C2 (en)	2009-08-05	2014-12-25	Biogen Idec Inc	Bicyclic aryl sphingosine 1-phosphate analogs
JP5934645B2 (ja)	2009-09-11	2016-06-15	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2011107530A2 (en)	2010-03-03	2011-09-09	Probiodrug Ag	Novel inhibitors
JP5688745B2 (ja)	2010-03-10	2015-03-25	プロビオドルグエージー	グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en)	2010-04-21	2011-10-27	Probiodrug Ag	Novel inhibitors
UA113507C2 (xx)	2011-02-07	2017-02-10		Модулятори s1p
EP2686313B1 (en)	2011-03-16	2016-02-03	Probiodrug AG	Benzimidazole derivatives as inhibitors of glutaminyl cyclase
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20160350201A1 (en) *	2015-05-27	2016-12-01	International Business Machines Corporation	Etl data flow design assistance through progressive context matching
WO2017004485A1 (en)	2015-07-02	2017-01-05	Raptor Pharmaceuticals Inc.	Ado-resistant cysteamine analogs and uses thereof
CN105362268A (zh) *	2015-12-15	2016-03-02	上海壹志医药科技有限公司	脱亚甲基小檗碱的药物用途
CN106526047A (zh) *	2016-11-15	2017-03-22	迪沙药业集团有限公司	R‑琥珀酸曲格列汀光学纯度的测定方法
ES2812698T3 (es)	2017-09-29	2021-03-18	Probiodrug Ag	Inhibidores de glutaminil ciclasa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6573287B2 (en) *	2001-04-12	2003-06-03	Bristo-Myers Squibb Company	2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
EP1406872B1 (en) *	2001-06-20	2007-12-19	Merck & Co., Inc.	Dipeptidyl peptidase inhibitors for the treatment of diabetes
ES2257555T3 (es) *	2001-06-20	2006-08-01	MERCK & CO., INC.	Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes.
DE10340800A1 (de) *	2002-12-20	2004-07-01	Merck Patent Gmbh	Funktionalisierung unreaktiver Substrate

2003
- 2003-12-09 EP EP03028211A patent/EP1541143A1/en not_active Withdrawn
2004
- 2004-12-09 CN CNA2004800404476A patent/CN1905868A/zh active Pending
- 2004-12-09 PL PL04803694T patent/PL1613304T3/pl unknown
- 2004-12-09 EP EP04803694A patent/EP1613304B1/en not_active Expired - Lifetime
- 2004-12-09 PT PT04803694T patent/PT1613304E/pt unknown
- 2004-12-09 DK DK04803694T patent/DK1613304T3/da active
- 2004-12-09 KR KR1020067013752A patent/KR100845397B1/ko not_active Expired - Fee Related
- 2004-12-09 AT AT04803694T patent/ATE372767T1/de not_active IP Right Cessation
- 2004-12-09 AU AU2004296553A patent/AU2004296553B2/en not_active Ceased
- 2004-12-09 RU RU2006119302/04A patent/RU2006119302A/ru not_active Application Discontinuation
- 2004-12-09 MX MXPA06006652A patent/MXPA06006652A/es not_active Application Discontinuation
- 2004-12-09 WO PCT/EP2004/014040 patent/WO2005056003A1/en not_active Ceased
- 2004-12-09 BR BRPI0417458-5A patent/BRPI0417458A/pt not_active IP Right Cessation
- 2004-12-09 JP JP2006543480A patent/JP2007513910A/ja not_active Withdrawn
- 2004-12-09 ES ES04803694T patent/ES2291966T3/es not_active Expired - Lifetime
- 2004-12-09 CA CA002548742A patent/CA2548742A1/en not_active Abandoned
- 2004-12-09 HR HR20070560T patent/HRP20070560T3/xx unknown
- 2004-12-09 SI SI200430469T patent/SI1613304T1/sl unknown
- 2004-12-09 DE DE602004008895T patent/DE602004008895T2/de not_active Expired - Fee Related
- 2004-12-09 US US10/582,054 patent/US20080027035A1/en not_active Abandoned
2006
- 2006-05-31 IL IL176062A patent/IL176062A0/en unknown
- 2006-06-08 NO NO20062644A patent/NO20062644L/no not_active Application Discontinuation
- 2006-06-08 ZA ZA200604719A patent/ZA200604719B/xx unknown
2007
- 2007-10-30 CY CY20071101404T patent/CY1106969T1/el unknown

Also Published As

Publication number	Publication date
ATE372767T1 (de)	2007-09-15
HRP20070560T3 (hr)	2008-01-31
DE602004008895D1 (en)	2007-10-25
KR100845397B1 (ko)	2008-07-09
ZA200604719B (en)	2007-12-27
IL176062A0 (en)	2006-10-05
HK1087022A1 (en)	2006-10-06
JP2007513910A (ja)	2007-05-31
CA2548742A1 (en)	2005-06-23
EP1541143A1 (en)	2005-06-15
AU2004296553B2 (en)	2008-09-04
AU2004296553A1 (en)	2005-06-23
EP1613304A1 (en)	2006-01-11
CN1905868A (zh)	2007-01-31
BRPI0417458A (pt)	2007-03-13
NO20062644L (no)	2006-09-07
SI1613304T1 (sl)	2007-12-31
RU2006119302A (ru)	2008-01-20
DE602004008895T2 (de)	2008-06-19
CY1106969T1 (el)	2012-09-26
US20080027035A1 (en)	2008-01-31
ES2291966T3 (es)	2008-03-01
WO2005056003A1 (en)	2005-06-23
KR20060108756A (ko)	2006-10-18
EP1613304B1 (en)	2007-09-12
MXPA06006652A (es)	2007-02-20
DK1613304T3 (da)	2008-01-21
PT1613304E (pt)	2007-11-14

Publication	Publication Date	Title
DE602004008895D1 (en)	2007-10-25	Dpp-iv-hemmer
EP1604989A8 (en)	2006-03-15	DPP-IV inhibitors
AP1614A (en)	2006-05-21	New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
MXPA03011039A (es)	2004-03-19	Nuevos compuestos heterociclicos, su preparacion y uso como medicamentos, particularmente como agentes anti-bacterianos.
WO2006005609A3 (de)	2006-03-16	Substituierte oxindol-derivate und diese enthaltende arzneimittel
ZA200309887B (en)	2004-07-20	Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
WO2003093269A3 (de)	2004-04-08	Substituierte pyrazolo-pyrimidin-4-one
WO2006048330A8 (en)	2006-10-05	11βετα-hsd1 inhibitors
PL376119A1 (pl)	2005-12-12	Nowe pochodne piperydyny do stosowania w leczeniustanów chorobowych pośredniczonych przez chemokiny
TW200500339A (en)	2005-01-01	Pyrrolidine derivatives, and process for the preparation
WO2005005389A3 (en)	2005-03-24	Malonamide derivatives
IL183636A0 (en)	2007-09-20	Quinoline derivative, use and production thereof, and drug containing the same
ZA200404752B (en)	2005-04-26	6-aminomorphinane derivatives method for the production and use thereof
MXPA03009548A (es)	2004-05-24	Arilsulfonamidas como agentes antivirales.
MXPA04006266A (es)	2004-09-27	Pirimidotriazinas como inhibidores de fosfatasa.
EP1598341A8 (en)	2006-03-01	DPP-IV inhibitors
NO20070089L (no)	2007-01-05	DPP-IV inhibitorer
MXPA04002282A (es)	2005-03-07	Nuevos compuestos y preparaciones como inhibidores de la catepsina.
GEP20084361B (en)	2008-04-29	Piperidinylcarbonyl-pyrro-lidines and their use as melanocortin agonists
IL173810A0 (en)	2006-07-05	Imidazopyridine derivatives and pharmaceutical compositions containing the same
MXPA03010120A (es)	2004-03-10	Arilcetonas substituidas.
MXPA06003345A (es)	2006-06-08	Derivados de aminopiridina como inhibidores de la no-sintasa inducible.
MXPA06000372A (es)	2006-03-30	Compuestos de silicio y su uso.
MXPA04005151A (es)	2004-08-11	Compuestos terapeuticos.
MXPA02001406A (es)	2002-08-12	Heterociclilos-2h-cromenos substituidos.